Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide

First Posted Date: 2010-10-22

Last Posted Date: 2017-02-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 3152

Registration Number: NCT01226966

Locations: 🇫🇷
Novo Nordisk Investigational Site, Paris La défense cedex, France

A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis

Phase 2

Completed

Conditions: Inflammation
Rheumatoid Arthritis

Interventions: Drug: placebo
Drug: NNC 0151-0000-0000

First Posted Date: 2010-10-19

Last Posted Date: 2017-02-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 34

Registration Number: NCT01223911

Locations: 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom

Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B

Completed

Conditions: Haemophilia A
Haemophilia B
Congenital Bleeding Disorder

Interventions: Drug: activated recombinant human factor VII

First Posted Date: 2010-10-13

Last Posted Date: 2015-04-16

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 51

Registration Number: NCT01220141

Comparison of Two Biphasic Insulin Aspart 30 Treatment Regimens in Subjects With Type 2 Diabetes Not Achieving HbA1c Treatment Targets on OADs Alone

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: biphasic insulin aspart 30

First Posted Date: 2010-10-06

Last Posted Date: 2014-10-30

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 245

Registration Number: NCT01215435

A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: liraglutide

First Posted Date: 2010-09-30

Last Posted Date: 2016-12-16

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1386

Registration Number: NCT01212133

Locations: 🇮🇳
Novo Nordisk Investigational Site, Bangalore, India

First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis

Phase 1

Completed

Conditions: Inflammation
Healthy
Rheumatoid Arthritis

Interventions: Drug: NNC0114-0000-0005
Drug: placebo

First Posted Date: 2010-09-24

Last Posted Date: 2017-02-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 64

Registration Number: NCT01208506

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation

Phase 2

Terminated

Conditions: Diabetes Mellitus, Type 1
Diabetes

Interventions: Drug: liraglutide
Drug: placebo

First Posted Date: 2010-09-21

Last Posted Date: 2017-03-30

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 3

Registration Number: NCT01206101

Locations: 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom

Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A

Phase 1

Completed

Conditions: Haemophilia A
Congenital Bleeding Disorder

Interventions: Drug: turoctocog alfa pegol

First Posted Date: 2010-09-20

Last Posted Date: 2017-02-10

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 27

Registration Number: NCT01205724

Locations: 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom

Comparison of Two Identical NN1250 Formulations in Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: insulin degludec

First Posted Date: 2010-09-01

Last Posted Date: 2013-11-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 26

Registration Number: NCT01193387

Observational Study of NovoPen Echo® on Safety and Treatment Satisfaction in Children and Adolescents With Type 1 Diabetes

Completed

Conditions: Delivery Systems
Diabetes
Diabetes Mellitus, Type 1

Interventions: Device: NovoPen Echo®

First Posted Date: 2010-08-12

Last Posted Date: 2017-02-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 358

Registration Number: NCT01180530

Locations: 🇸🇪
Novo Nordisk Investigational Site, Malmö, Sweden

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy